Host-microbiota interactions: a novel insight into the aryl hydrocarbon receptor in Parkinson’s disease

Key Points

• The aim is to explore the relationship between the AHR-gut microbiota axis and the pathogenesis of Parkinson's disease.
• Review of clinical and preclinical studies examining AHR and gut microbiota in PD.
• Synthesis of existing evidence on AHR's role in PD pathogenesis.
• Discussion of potential pharmacological interventions targeting the AHR-gut microbiota axis.
• Evidence indicates a link between AHR activity and gut microbiota composition in PD.
• Pharmacological targeting of the AHR-gut microbiota axis shows promise as a therapeutic strategy for PD.